For the quarter ending 2026-03-31, BBOT had -$321,029K decrease in cash & cash equivalents over the period. -$35,941K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | -42,106 | -38,797 | -95,247 |
| Depreciation of property and equipment | 74 | 84 | 196 |
| Stock-based compensation | 3,871 | 2,946 | 2,927 |
| Fair value of common stock issuable to related party | - | - | -7,769 |
| Fair value of common stock issued to related party | - | -7,769 | - |
| Change in fair value of participation right liability | 0 | 0 | 725 |
| Net accretion of premiums on marketable securities | 74 | 89 | 1,171 |
| Amortization of right-of-use assets | 112 | 110 | 220 |
| Prepaid expense and other currents assets | 7,531 | -948 | 4,365 |
| Other non-current assets | -1,329 | 7,183 | 398 |
| Accounts payble | 10,685 | -2,417 | 577 |
| Accrued compensation and benefits | -3,729 | 1,258 | 667 |
| Accrued research and development liabilities | -31 | 1,844 | 15,831 |
| Accrued professional services | 880 | -582 | 480 |
| Operating lease liabilities | -123 | -121 | 74 |
| Other accrued liabilities | 305 | 81 | -7 |
| Balances due to and from related parties | -421 | 316 | -62 |
| Net cash used in operating activities | -35,917 | -42,234 | -71,660 |
| Maturities of marketable securities | 26,262 | 28,883 | 128,976 |
| Purchases of marketable securities | 311,645 | 21,044 | 62,881 |
| Change in related party receivables related to cash pooling arrangement | - | 0 | 0 |
| Purchases of property and equipment | 24 | 73 | 533 |
| Net cash (used in) provided by investing activities | -285,407 | 7,766 | 65,562 |
| Proceeds from reverse recapitalization and pipe financing | - | 0 | 373,457 |
| Payment of deferred transaction costs | 121 | 631 | 11,691 |
| Issuance of series a redeemable convertible preferred stock | - | 0 | 0 |
| Issuance of series b redeemable convertible preferred stock, net of issuance costs | - | 0 | 22,222 |
| Contribution from bridgebio pharma | - | 0 | 0 |
| Exercise of common stock options for cash | 416 | 45 | - |
| Net cash provided by (used in) financing activities | 295 | -586 | 383,988 |
| Net increase in cash, cash equivalents, and restricted cash | -321,029 | -35,054 | 377,890 |
| Cash, cash equivalents, and restricted cash at beginning of period | 373,819 | 408,873 | 30,983 |
| Cash, cash equivalents, and restricted cash at end of period | 52,790 | 373,819 | 408,873 |
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)